Aligos Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALG-000184 / Aligos Therap
B-SUPREME, NCT06963710: A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B

Not yet recruiting
2
200
NA
ALG-000184, TDF
Aligos Therapeutics
Chronic Hepatitis B Infection
03/27
08/28
NCT04536337: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Active, not recruiting
1
165
RoW
ALG-000184, Placebo, Entecavir
Aligos Therapeutics
Chronic Hepatitis B
06/25
06/25
NCT06672900: A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Active, not recruiting
1
24
US
Carbamazepine, Itraconazole (Sporanox), ALG-000184
Aligos Therapeutics
Healthy Volunteer
07/25
07/25
ALG-020572 / Aligos Therap
NCT05001022: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Terminated
1
40
Europe, RoW
ALG-020572, Placebo
Aligos Therapeutics
Chronic Hepatitis B
07/22
07/22
ALG-125755 / Aligos Therap
NCT05561530: A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Terminated
1
57
Europe, RoW
ALG-125755, Placebo
Aligos Therapeutics
Chronic Hepatitis B
06/23
06/23
ALG-055009 / Aligos Therap
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Completed
2
102
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
08/24
09/24
ALG-055009-301, NCT05090111: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

Completed
1
98
Europe
ALG-055009, Placebo
Aligos Therapeutics
NASH - Nonalcoholic Steatohepatitis
06/23
06/23
NCT06191991: A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

Completed
1
14
US
Atorvastatin, ALG-055009, Rosuvastatin
Aligos Therapeutics
Healthy Volunteers
11/23
12/23
ALG-055009-304, NCT06959888: A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

Recruiting
1
8
US
ALG-055009
Aligos Therapeutics
Healthy Volunteer Study
04/25
05/25
ALG-093453 / Aligos Therap
No trials found
ALG-005398 / Aligos Therap
No trials found
ALG-093702 / Aligos Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALG-000184 / Aligos Therap
B-SUPREME, NCT06963710: A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B

Not yet recruiting
2
200
NA
ALG-000184, TDF
Aligos Therapeutics
Chronic Hepatitis B Infection
03/27
08/28
NCT04536337: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Active, not recruiting
1
165
RoW
ALG-000184, Placebo, Entecavir
Aligos Therapeutics
Chronic Hepatitis B
06/25
06/25
NCT06672900: A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Active, not recruiting
1
24
US
Carbamazepine, Itraconazole (Sporanox), ALG-000184
Aligos Therapeutics
Healthy Volunteer
07/25
07/25
ALG-020572 / Aligos Therap
NCT05001022: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Terminated
1
40
Europe, RoW
ALG-020572, Placebo
Aligos Therapeutics
Chronic Hepatitis B
07/22
07/22
ALG-125755 / Aligos Therap
NCT05561530: A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Terminated
1
57
Europe, RoW
ALG-125755, Placebo
Aligos Therapeutics
Chronic Hepatitis B
06/23
06/23
ALG-055009 / Aligos Therap
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Completed
2
102
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
08/24
09/24
ALG-055009-301, NCT05090111: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

Completed
1
98
Europe
ALG-055009, Placebo
Aligos Therapeutics
NASH - Nonalcoholic Steatohepatitis
06/23
06/23
NCT06191991: A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

Completed
1
14
US
Atorvastatin, ALG-055009, Rosuvastatin
Aligos Therapeutics
Healthy Volunteers
11/23
12/23
ALG-055009-304, NCT06959888: A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

Recruiting
1
8
US
ALG-055009
Aligos Therapeutics
Healthy Volunteer Study
04/25
05/25
ALG-093453 / Aligos Therap
No trials found
ALG-005398 / Aligos Therap
No trials found
ALG-093702 / Aligos Therap
No trials found

Download Options